KaydedilenlerDerginizi ekleyin

Dergiler / Balıkesir Sağlık Bilimleri Dergisi / 2026 / Volume: 15 Issue: 3

The Effects of Passiflora Syrup on The Blood and Tissue Concentrations of Fluoxetine in Rats

Büşra Aslan Akyol(Balıkesir Üniversitesi)0000-0002-4123-8408
Esra Korkmaz(Balikesir University)0009-0008-5075-9257
İrem Ünal(Balikesir University)0009-0009-3669-8328
Ramazan Öztop(Balikesir University)0009-0006-2212-9106
Ensat Yar(Balikesir University)0009-0000-4693-6363
Eyüp Tolga Akyol(Balikesir University)0000-0002-9775-7557
Cengiz Gökbulut(Balikesir University)0000-0002-4912-7307
Sayfa
—
Yayın Tarihi
2026-10-08
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Potential pharmacokinetic interactions and toxicity risks should be considered when using herbal supplements in combination with antidepressant medications.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Interactions between medications and herbal supplements can lead to clinically unpredictable adverse effects.
📊
Temel Bulgular & Veri:Fluoxetine, a commonly prescribed antidepressant, is highly susceptible to herbal-drug interactions due to its extensive metabolism via cytochrome P450 enzymes.
💡
Sonuç & Katkı:Conclusion: Potential pharmacokinetic interactions and toxicity risks should be considered when using herbal supplements in combination with antidepressant medications.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Fluoxetine · Passiflora · Drug-herb interaction

Abstract

Objective: Interactions between medications and herbal supplements can lead to clinically unpredictable adverse effects. Fluoxetine, a commonly prescribed antidepressant, is highly susceptible to herbal-drug interactions due to its extensive metabolism via cytochrome P450 enzymes. This study aimed to investigate possible interactions between fluoxetine and passiflora, which are frequently used to treat anxiety and insomnia. Materials and Methods: Twelve male Wistar Albino rats, ages three to four months, were split into two experimental groups of six each: fluoxetine and passiflora (40 mg/kg and 1 mL/kg, respectively) and fluoxetine alone (40 mg/kg). Gavage was used to provide treatments orally. Results: Fluoxetine concentrations in kidney and brain tissues were significantly greater in the passiflora group, but there was no significant rise in blood or liver levels, according to high-performance liquid chromatography (HPLC) examination of blood and tissue samples taken at the conclusion of the experiment. Furthermore, concentrations of norfluoxetine, the active metabolite, were significantly increased in liver, kidney, and brain tissues in the passiflora group. These findings demonstrate that administration of passiflora significantly alters the tissue distribution profiles of fluoxetine and its active metabolite. Conclusion: Potential pharmacokinetic interactions and toxicity risks should be considered when using herbal supplements in combination with antidepressant medications.

🔖

Bu Makaleye Atıf Yap

Akyol, B. A., Korkmaz, E., Ünal, İ., Öztop, R., Yar, E., Akyol, E. T., Gökbulut, C. (2026). The Effects of Passiflora Syrup on The Blood and Tissue Concentrations of Fluoxetine in Rats. Balıkesir Sağlık Bilimleri Dergisi, Volume: 15 Issue: 3. https://doi.org/10.53424/balikesirsbd.1981765

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (31)

  1. Altamura, A. C., Moro, A. R., & Percudani, M. (1994). Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics, 26(3), 201-214. https://doi.org/10.2165/00003088-199426030-00004
  2. Anderson, D., Hinchcliffe, J., Jackson, M., & Robinson, E. (2025). Is poor dose selection undermining the translational validity of antidepressant research involving animal models?. BioRxiv, 2025-10. https://doi.org/10.1101/2025.10.25.684561
  3. Blecharz-Klin, K., Pyrzanowska, J., Piechal, A., Joniec-Maciejak, I., Wawer, A., Jawna-Zboińska, K.,. & Widy-Tyszkiewicz, E. (2024). Effect of Passiflora incarnata L. extract on exploratory behaviour and neurotransmitters level in structures involved in motor functions in rats. Journal of Pre-Clinical and Clinical Research, 18(1), 1-10.
  4. Carrasco, M. C., Vallejo, J. R., Pardo‐de‐Santayana, M., Peral, D., Martín, M. Á., & Altimiras, J. (2009). Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytotherapy Research, 23(12), 1795-1796. https://doi.org/10.1002/ptr.2847
  5. Catterson, M. L., & Preskorn, S. H. (1996). Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacology & Toxicology, 78(4), 203-208. https://doi.org/10.1111/j.1600-0773.1996.tb00206.x
  6. Gokbulut, C., Korkut, O., Aksoz, E., Baykan, H., & l, B. A. (2025). A rapid and simple analytical methodology for therapeutic drug monitoring of selective serotonin reuptake inhibitors in human plasma by high‐pressure liquid chromatography. Separation Science Plus, 8(2), e70006. https://doi.org/10.1002/sscp.70006
  7. Gómez-Garduño, J., León-Rodríguez, R., Alemón-Medina, R., Pérez-Guillé, B. E., Soriano-Rosales, R. E., González-Ortiz, A.,. & Rivera-Espinosa, L. (2022). Phytochemicals that interfere with drug metabolism and transport, modifying plasma concentration in humans and animals. Dose-Response, 20(3), 15593258221120485. https://doi.org/10.1177/15593258221120
  8. Harris, D. C. (2007). Quantitative Chemical Analysis. NY: W.H. Freeman and Company. Harvey, A. T., & Preskorn, S. H. (2001). Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. Journal of Clinical Psychopharmacology, 21(2), 161-166.
  9. Hemeryck, A., & Belpaire, F. M. (2002). Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism, 3(1), 13-37. https://doi.org/10.2174/1389200023338017
  10. Jafarpoor, N., Abbasi-Maleki, S., Asadi-Samani, M., & Khayatnouri, M. H. (2014). Evaluation of antidepressant-like effect of hydroalcoholic extract of Passiflora incarnata in animal models of depression in male mice. Journal of HerbMed Pharmacology, 3(1), 41-45.
  11. Justil-Guerrero, H. J., Arroyo-Acevedo, J. L., Rojas-Armas, J. P., García-Bustamante, C. O., Palomino-Pacheco, M., Almonacid-Román, R. D., & Calva Torres, J. W. (2024). Evaluation of Bioactive Compounds, Antioxidant Capacity, and Anti-Inflammatory Effects of Lipophilic and Hydrophilic Extracts of the Pericarp of Passiflora tripartita var. mollissima at Two Stages of Ripening. Molecules, 29(20), 4964. https://doi.org/10.3390/molecules29204964
  12. Kapadia, G. J., Azuine, M. A., Tokuda, H., Hang, E., Mukainaka, T., Nishino, H., & Sridhar, R. (2002). Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein–Barr virus early antigen activation. Pharmacological Research, 45(3), 213-220. https://doi.org/10.1006/phrs.2001.0936
  13. Kaur, G., Voith, V. L., & Schmidt, P. L. (2016). The use of fluoxetine by veterinarians in dogs and cats: a preliminary survey. Veterinary Record Open, 3(1), e000146. https://doi.org/10.1136/vetreco-2015-000146 Labbozzetta, M., Poma, P., Tutone, M., McCubrey, J. A., Sajeva, M., & Notarbartolo, M. (2022). Phytol and heptacosane are possible tools to overcome multidrug resistance in an in vitro model of acute myeloid leukemia. Pharmaceuticals, 15(3), 356. https://doi.org/10.3390/ph15030356
  14. Liu, Z. Q., Zhu, B., Tan, Y. F., Tan, Z. R., Wang, L. S., Huang, S. L.,. & Zhou, H. H. (2002). O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics, 300(1), 105-111. https://doi.org/10.1124/jpet.300.1.105
  15. Marchart, E., Krenn, L., & Kopp, B. (2003). Quantification of the flavonoid glycosides in Passiflora incarnata by capillary electrophoresis. Planta Medica, 69(05), 452-456. https://doi.org/10.1055/s-2003-39699
  16. Margolis, J. M., O’Donnell, J. P., Mankowski, D. C., Ekins, S., & Obach, R. S. (2000). (R)-,(S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metabolism and Disposition, 28(10), 1187-1191. https://doi.org/10.1016/S0026-895X(24)12048-2
  17. Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28(9), 1031-1037. https://doi.org/10.1016/S0090-9556(24)15182-3
  18. Murray, M., & Murray, K. (2003). Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica, 33(10), 973-987. https://doi.org/10.1080/00498250310001602748
  19. Nojoumi, M., Ghaeli, P., Salimi, S., Sharifi, A., & Raisi, F. (2016). Effects of Passion Flower Extract, as an Add-on Treatment to Sertraline, on Reaction Time in Patients‎ with Generalized Anxiety Disorder: a Double-blind Placebo-Controlled Study. Iranian Journal of Psychiatry, 11(3), 191.
  20. Patel, S. S., Saleem, T. M., Ravi, V., Shrestha, B., Verma, N. K., & Gauthaman, K. (2009). Passiflora incarnata Linn: A phytopharmacological review. International Journal of Green Pharmacy (IJGP), 3(4), 277-280.
  21. Perez-Caballero, L., Torres-Sanchez, S., Bravo, L., Mico, J. A., & Berrocoso, E. (2014). Fluoxetine: a case history of its discovery and preclinical development. Expert Opinion on Drug Discovery, 9(5), 567-578. https://doi.org/10.1517/17460441.2014.907790
  22. Riaz, A., & Khan, R. A. (2016). Anticoagulant, antiplatelet and antianemic effects of Punica granatum (pomegranate) juice in rabbits. Blood Coagulation & Fibrinolysis, 27(3), 287-293. https://doi.org/10.1097/MBC.0000000000000415
  23. Sager, J. E., Lutz, J. D., Foti, R. S., Davis, C., Kunze, K. L., & Isoherranen, N. (2014). Fluoxetine‐and norfluoxetine‐mediated complex drug–drug interactions: In vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clinical Pharmacology & Therapeutics, 95(6), 653-662. https://doi.org/10.1038/clpt.2014.50
  24. Spina, E., Avenoso, A., Scordo, M. G., Ancione, M., Madia, A., Gatti, G., & Perucca, E. (2002). Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology, 22(4), 419-423.
  25. Vaswani, M., Linda, F. K., & Ramesh, S. (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27(1), 85-102. https://doi.org/10.1016/S0278-5846(02)00338-X
  26. Wood, A. J. J., & Gram, L. F. (1994). Fluoxetine. New England Journal of Medicine, 33(20), 1354-1361. https://doi.org/10.1056/NEJM199411173312008.
  27. Yalcin, S. (2020). Molecular docking, drug likeness, and ADMET analyses of passiflora compounds as P-glycoprotein (P-gp) inhibitor for the treatment of cancer. Current Pharmacology Reports, 6(6), 429-440. https://doi.org/10.1007/s40495-020-00241-6
  28. Zhou, Y. J., Tan, F., & Deng, J. (2008). Update review of Passiflora. Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi= China Journal of Chinese Materia Medica, 33(15), 1789-1793.
  29. Blecharz-Klin, K., Pyrzanowska, J., Piechal, A., Joniec-Maciejak, I., Wawer, A., Jawna-Zboińska, K.,. & Widy-Tyszkiewicz, E. (2024). Effect of Passiflora incarnata L. extract on exploratory behaviour and neurotransmitters level in structures involved in motor functions in rats. Journal of Pre-Clinical and Clinical Research, 18(1), 1-10.
  30. Gómez-Garduño, J., León-Rodríguez, R., Alemón-Medina, R., Pérez-Guillé, B. E., Soriano-Rosales, R. E., González-Ortiz, A.,. & Rivera-Espinosa, L. (2022). Phytochemicals that interfere with drug metabolism and transport, modifying plasma concentration in humans and animals. Dose-Response, 20(3), 15593258221120485. https://doi.org/10.1177/15593258221120
  31. Liu, Z. Q., Zhu, B., Tan, Y. F., Tan, Z. R., Wang, L. S., Huang, S. L.,. & Zhou, H. H. (2002). O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics, 300(1), 105-111. https://doi.org/10.1124/jpet.300.1.105